Company Overview of MacroGenics, Inc.
MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination th...
9704 Medical Center Drive
Rockville, MD 20850
Founded in 2000
Key Executives for MacroGenics, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $535.6K
Chief Financial Officer, Senior Vice President and Secretary
Total Annual Compensation: $344.4K
Chief Medical Officer and Senior Vice President of Clinical Development
Total Annual Compensation: $423.4K
Chief Scientific Officer and Senior Vice President of Research
Total Annual Compensation: $369.6K
Chief Business Officer and Senior Vice President of Business Development & Portfolio Management
Total Annual Compensation: $350.2K
Compensation as of Fiscal Year 2016.
MacroGenics, Inc. Key Developments
MacroGenics, Inc. Presents at European Society for Medical Oncology Annual Congress, ESMO 2017, Sep-10-2017 11:00 AM
Sep 11 17
MacroGenics, Inc. Presents at European Society for Medical Oncology Annual Congress, ESMO 2017, Sep-10-2017 11:00 AM. Venue: Madrid, Spain.
MacroGenics Reports 'Encouraging Anti-Leukemic Activity of Drug to Treat Bone Marrow-Cancer
Sep 11 17
MacroGenics reported encouraging results from a phase 1 trial of its drug flotetuzumab to treat acute myeloid leukemia and myelodysplastic syndrome, which are types of bone-marrow maladies that lead to bone and blood cancers. The company also reported flotetuzumab demonstrated acceptable tolerability in the dose escalation portion of the study, and that further clinical results would be presented at future scientific conferences.
MacroGenics Advances Two Clinical DART® Molecules
Sep 5 17
MacroGenics, Inc. announced the advancement of two of its proprietary bispecific DART product candidates. This progress includes: a first patient has been dosed with MGD013, a DART molecule that recognizes PD-1 and LAG-3; and the submission of an Investigational New Drug (IND) application with the FDA for MGD014, a DART molecule that targets HIV-infected cells and CD3. MacroGenics retains worldwide rights to both of these product candidates. MGD013 recognizes both PD-1 and LAG-3 and was designed to enable the co-blockade of these two immune checkpoint molecules co-expressed on T cells. MGD013 has a prolonged serum half-life and is being developed for the potential treatment of a wide range of cancers, including both solid tumors and hematological malignancies. MGD013 is MacroGenics’ first in a series of product candidates that recognize multiple immune regulator targets as a single recombinant molecule. MGD014 is a bispecific, Fc-bearing DART molecule that targets HIV-infected cells and CD3-expressing T cells, and is being developed by MacroGenics under a contract awarded in September 2015 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. NIAID recently notified MacroGenics that it was exercising the first of two options under the HIV contract, funding MacroGenics’ advancement of MGD014 into Phase 1 clinical trials as well as the development and testing of a second DART molecule. Under the exercised option, funding of up to $10.8 million is available to MacroGenics for these development efforts. The second option, if later exercised by NIAID, would provide up to an additional $6.3 million for continued development efforts on one or both molecules. Assuming MGD014 IND clearance by the FDA, the Company believes this molecule will be the first clinical bispecific molecule targeting an infectious agent.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|